1. Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
Sabine Kayser, Ramy Rahmé[…] & Pau Montesinos
Leukemia, 2020, 34: 2333–2341.
包含或不包含三氧化二砷的一線方案治療老年（≥70歲）急性早幼粒細胞白血病的結果分析：一項國際合作研究
2. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia
Christopher A. Eide, Stephen E. Kurtz[…] & Jeffrey W. Tyner
Leukemia, 2020, 34: 2342–2353.
同時使用Btk抑制劑ibrutinib和BCL2抑制劑venetoclax作為急性髓系白血病的一種治療策略
3. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Lydia Scarfò, Thomas Chatzikonstantinou[…] & Paolo Ghia
Leukemia, 2020, 34: 2354–2363.
慢性淋巴細胞白血病病人COVID-19的嚴重程度和病死率：ERIC和CLL Campus的一項聯合研究
4. Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia
Weiqi Huang, Bin Liu & Elizabeth A. Eklund
Leukemia, 2020, 34: 2364–2374.
天然免疫應答在慢性髓系白血病復發和原始細胞危象中的作用研究
5. Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment
Chengxiang Xia, Tongjie Wang[…] & Jinyong Wang
Leukemia, 2020, 34: 2375–2383.
間充質幹細胞通過巨噬細胞介導的骨髓微環境功能重塑作用抑制白血病進展
6. Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission
Qiubai Li, Lei Chen[…] & Yu Hu
Leukemia, 2020, 34: 2384–2391.
癌症在<65歲以及非完全緩解的患者中均增加COVID-19的院內死亡風險
7. A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study
Xiao-Peng Tian, Dan Xie[…] & Qing-Qing Cai
Leukemia, 2020, 34: 2392–2404.
用於預測成人T淋巴細胞母細胞淋巴瘤生存的一組基因表達特徵：一項多中心研究
8. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma
Masaharu Kawashima, Joaquim Carreras[…] & Ai Kotani
Leukemia, 2020, 34: 2405–2417.
經典型霍奇金淋巴瘤中通過對腫瘤細胞的「胞啃作用」單核細胞膜上PD-L1/L2蛋白水平迅速上升
9. Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq
Zhenhua Li, Nan Jiang[…] & Allen Eng-Juh Yeoh
Leukemia, 2020, 34: 2418–2429.
應用RNA測序檢測IGH疾病克隆監測兒童急性B淋巴細胞白血病的微小殘留病
10. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari[…] & Meletios Athanasios Dimopoulos
Leukemia, 2020, 34: 2430–2440.
核輸出抑制劑selinexor用於治療多發性骨髓瘤的整體安全性評價：對437例臨床試驗受試者的治療經驗
11. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7
Elena Crisà, Austin G. Kulasekararaj[…] & Ghulam J. Mufti
Leukemia, 2020, 34: 2441–2450.
體細胞突變對具有-7和7q-細胞遺傳學異常的骨髓異常增生症候群病人的影響
12. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index
Fabio Efficace, Francesco Cottone[…] & Marco Vignetti
Leukemia, 2020, 34: 2451–2459.
IPSS-R評分較IPSS指數更為準確地評價MDS病人的疲勞程度
13. Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells
Pragya Srivastava, Stephanie L. Tzetzo[…] & Michael J. Nemeth
Leukemia, 2020, 34: 2460–2472.
抑制LSD1可恢復骨髓異常增生症候群中前體細胞向CD141Hi經典樹突狀細胞分化